AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36443174
Drug: Alpha-1 antitrypsin
RxNorm normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-1 antitrypsin (A1AT) (90 mg/kg x 6 doses)
Trial: 33819452
Drug: High-protein, high-calorie
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein, high-calorie oral nutritional supplements (ONS), 2 bottles daily for 3 months
Trial: 33685706
Drug: Sedated: lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedated: lidocaine cornual nerve block, 0.5 mg/kg meloxicam (subcutaneously), and 0.2 mg/kg xylazine (intramuscularly)
Trial: 35788146
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no laser treatment)
Trial: 32195639
Drug: Laser group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser group (445-nm diode laser treatment)
Trial: 34302745
Drug: Dapagliflozin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin (10 mg daily orally)
Trial: 32791501
Drug: Cognitive-Behavioral Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioral Therapy (CBT) and Well-Being Therapy (WBT)
Trial: 34116270
Drug: Chemotherapy-induced ovarian
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy-induced ovarian failure (CIOF) after anthracycline/taxane-based chemotherapy
Trial: 34116270
Drug: Regain of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regain of premenopausal hormone levels after chemotherapy
Trial: 32147076
Drug: Green coffee
RxNorm normalized name: Green coffee bean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green coffee extract (GCE) 400 mg daily for 8 weeks
Trial: 39039548
Drug: Propofol-based total
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol-based total intravenous anesthesia (TIVA)
Trial: 32990215
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment and Placebo
Trial: 35334388
Drug: Vasopressin administration
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vasopressin administration
Trial: 34959949
Drug: Carrot-derived rhamnogalacturonan-I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carrot-derived rhamnogalacturonan-I (cRG-I) at 0.3 g/day
Trial: 36453726
Drug: Bone channeling
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone channeling augmentation
Trial: 37783947
Drug: MSC therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSC therapy
Trial: 32127275
Drug: High heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High heparin dose (600 IU/kg)
Trial: 32127275
Drug: Low heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low heparin dose (300 IU/kg)
Trial: 34511049
Drug: Probiotic (Lab4)
RxNorm normalized name: Rezyst Probiotic
DrugBank: Bifidobacterium longum (DB19248)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic (Lab4) plus 50 mg vitamin C
Trial: 33213530
Drug: Favipiravir plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Favipiravir plus standard treatment for COVID‐19 (loading dose of 3600mg on day 1, followed by 800mg 12 hours apart for 9 days)
Trial: 33213530
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment for COVID‐19 (at the discretion of the treating clinician)
Trial: 32900856
Drug: NP-administered POCUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NP-administered POCUS
Trial: 35241538
Drug: Cisplatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (40 mg/m2)
Trial: 32725411
Drug: Paclitaxel-coated drug-eluting
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel-coated drug-eluting stents (DES)
Trial: 35022480
Drug: Lymphatic Contrast
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymphatic Contrast Enhanced Ultrasound (LCEUS) with Sonazoid injection
Trial: 36362489
Drug: Doll Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doll Therapy Intervention (DTI)
Trial: 32173165
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard preparation)
Trial: 34543161
Drug: Valsartan 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 0.25 mg/kg/day (CKD subgroup)
Trial: 34543161
Drug: Valsartan 4
RxNorm normalized name: valsartan 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 4 mg/kg/day (non-CKD subgroup)
Trial: 33262414
Drug: Sublingual fentanyl
RxNorm normalized name: fentanyl Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual fentanyl 100 µg
Trial: 38528476
Drug: Lasmiditan 100
RxNorm normalized name: lasmiditan 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lasmiditan 100 mg
Trial: 32452181
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (Fengshi spine fixed-point rotation reduction plus routine dehydration and anti-inflammation)
Trial: 34916216
Drug: Margetuximab plus
RxNorm normalized name: Margetuximab
DrugBank: Margetuximab (DB14967)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Margetuximab plus chemotherapy
Trial: 35418312
Drug: Margetuximab plus
RxNorm normalized name: Margetuximab
DrugBank: Margetuximab (DB14967)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Margetuximab plus chemotherapy in CD16A-158F allele carriers
Trial: 32870298
Drug: Low tidal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low tidal volume group (6 mL/kg predicted body weight)
Trial: 32870298
Drug: Conventional tidal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional tidal volume group (10 mL/kg predicted body weight)
Trial: 34772441
Drug: Oral antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antibiotic treatment
Trial: 34380867
Drug: Single-dose regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose regimen of 4 L PEG (Nulytely) administered a day before the procedure
Trial: 32932235
Drug: Flavonoid supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavonoid supplementation (678 mg FLAVs including quercetin, green tea catechins, and bilberry anthocyanins)
Trial: 33340297
Drug: Fampridine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fampridine (10 mg, 2 times a day for 24 weeks)
Trial: 33340297
Drug: Placebo (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (same administration as fampridine)
Trial: 33340297
Drug: Fampridine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fampridine (10 mg, 2 times a day for 12 weeks after placebo)
Trial: 32006156
Drug: 23-month ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 23-month ticagrelor monotherapy following 1-month dual antiplatelet therapy (DAPT)
Trial: 32006156
Drug: 12-month aspirin
RxNorm normalized name: aspirin / menthol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-month aspirin monotherapy following 12-month DAPT
Trial: 33971940
Drug: Naoxintong (NXT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naoxintong (NXT) capsule (3 pills, 3 times daily for 12 weeks)
Trial: 32814493
Drug: Laxatives only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laxatives only (Control Group)
Trial: 36657898
Drug: HMB (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMB (3 g/day)
Trial: 35731653
Drug: Bivalent prefusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent prefusion F (RSVpreF) vaccine
Trial: 36384907
Drug: Vibegron 75
RxNorm normalized name: vibegron 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vibegron 75 mg
Trial: 32639468
Drug: Ambrisentan (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambrisentan (2.5 mg in suspension, daily for 3 days)
Trial: 34066577
Drug: Multi-nutrient fortified
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-nutrient fortified dairy-based drink (400 mL)
Trial: 34066577
Drug: Multi-nutrient fortified
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-nutrient fortified dairy-based drink (600 mL)
Trial: 36200642
Drug: Reduced-dose PTCy/ATG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced-dose PTCy/ATG (40 mg/kg/d on days 3 and 4 for PTCy; 2.5 mg/kg on day 8 for ATG)
Trial: 35840747
Drug: Standard-dose ATG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose ATG (10 mg/kg)
Trial: 32296931
Drug: Hesperidin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hesperidin (1 g/day)
Trial: 32296931
Drug: Flaxseed (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed (30 g/day)
Trial: 32296931
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of flaxseed and hesperidin (30 g flaxseed and 1 g hesperidin)
Trial: 33284796
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no supplement)
Trial: 33752423
Drug: Nomogram model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nomogram model developed using independent prognostic factors (Grade, T stage, liver surgery, chemotherapy, radiation recode, alpha‐fetoprotein level, fibrosis score, tumor size group, M stage)
Trial: 32280089
Drug: Hydromethylthionine 200
RxNorm normalized name: Hydromethylthionine mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromethylthionine 200 mg/day
Trial: 38082227
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg ketamine
Trial: 36114799
Drug: Valbenazine 40-mg
RxNorm normalized name: valbenazine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valbenazine 40-mg
Trial: 36114799
Drug: Valbenazine 80-mg
RxNorm normalized name: valbenazine 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valbenazine 80-mg
Trial: 33653802
Drug: Rapamycin 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapamycin 0.5 mg
Trial: 36145067
Drug: LCHF diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCHF diet (<50 g CHO p/day)
Trial: 615901264
Drug: Double placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double placebo (injections and gel)
Trial: 37100187
Drug: Atomoxetine 80
RxNorm normalized name: atomoxetine 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine 80 mg daily
Trial: 36477706
Drug: Sugammadex 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex 1.0 mg/kg
Trial: 32940653
Drug: Timolol thermosensitive
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol thermosensitive gel (0.1%) applied twice daily for 8 weeks
Trial: 32940653
Drug: Placebo thermosensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo thermosensitive gel applied twice daily for 8 weeks
Trial: 32940653
Drug: Timolol thermosensitive
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol thermosensitive gel (0.1%)
Trial: 32940653
Drug: Placebo thermosensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo thermosensitive gel
Trial: 32619077
Drug: Ribociclib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribociclib plus endocrine therapy
Trial: 32398199
Drug: Double-dose rifampicin
RxNorm normalized name: rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Double-dose rifampicin (20 mg/kg/d)
Trial: 36055669
Drug: IV TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV TXA 2 g
Trial: 32746647
Drug: Lanreotide (LAN)
DrugBank: Lanreotide (DB06791)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lanreotide (LAN) and antidiarrhoeal treatments (TAD)
Trial: 32746647
Drug: Antidiarrhoeal treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidiarrhoeal treatments only (TADS)
Trial: 33166718
Drug: Atezolizumab (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab (1200 mg fixed dose)
Trial: 38751442
Drug: Docetaxel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (75 mg/m2)
Trial: 32472012
Drug: NOMAC/E2 (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NOMAC/E2 (2.5 mg nomegestrol acetate and 1.5 mg estradiol)
Trial: 32472012
Drug: GS/EE (0.075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GS/EE (0.075 mg gestodene and 0.02 mg ethinyl estradiol)
Trial: 32766808
Drug: Osteopathic Manipulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic Manipulative Medicine (OMM)
Trial: 34022937
Drug: Single-dose tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose tranexamic acid
Trial: 36201813
Drug: Internet-delivered treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered treatment for anxiety and depression over 8 weeks
Trial: 34503735
Drug: HER2-targeted therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HER2-targeted therapy
Trial: 33676429
Drug: Blended AUD
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blended AUD treatment
Trial: 33676429
Drug: Face-to-face treatment
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face-to-face treatment only (TAU)
Trial: 34801738
Drug: Umifenovir (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Umifenovir (800 mg BID, maximum 14 days)
Trial: 36426809
Drug: Morphine (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (group M)
Trial: 35941536
Drug: Oxycodone (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone (group O)
Trial: 32692113
Drug: Antiretroviral Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral Therapy (ART)
Trial: 36200632
Drug: Direct-to-consumer advertising
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct-to-consumer advertising for heart disease medications (treatment 1)
Trial: 36200632
Drug: Direct-to-consumer advertising
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct-to-consumer advertising for heart disease medications with price disclosure (treatment 2)
Trial: 34147912
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate nasal spray (100 mcg twice daily) with olfactory training for 4 weeks
Trial: 32066345
Drug: Linear accelerator
RxNorm normalized name: Aspalathus linearis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linear accelerator (standard treatment)
Trial: 33279295
Drug: Quiet group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quiet group (treatment)
Trial: 35669313
Drug: Depot Medroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depot Medroxyprogesterone Acetate Intramuscular Injection (DMPA-IM)
Trial: 35669313
Drug: Levonorgestrel Implant
RxNorm normalized name: levonorgestrel IMPLANT KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel Implant (LNG)
Trial: 32840417
Drug: Pazopanib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 800 mg once per day
Trial: 34815708
Drug: Galcanezumab 120
RxNorm normalized name: Galcanezumab 120 mg/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galcanezumab 120 mg
Trial: 32930994
Drug: Open-label treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label treatment (previous placebo)
Trial: 32888343
Drug: Electronic tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic tablets
Trial: 35554079
Drug: TrimRox, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TrimRox, a stimulant‐ and sugar‐free Prodosomed® TRCAP21 nutraceutical technology, utilizing six standardized extracts.
Trial: 38281089
Drug: Direct oral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct oral anticoagulants (DOACs)
Trial: 34585215
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses 10 mg/kg every 4 weeks for 72 weeks
Trial: 34585215
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses 20 mg/kg every 4 weeks for 72 weeks
Trial: 34379025
Drug: Placebo 3300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 3300 mg/day
Trial: 34952747
Drug: Culturally tailored
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally tailored contingency management (CM) intervention targeting alcohol abstinence; 12 weeks duration, incentives for negative urine tests (EtG < 150 ng/mL)
Trial: 33043352
Drug: Autologous concentrated
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous concentrated growth factor fibrin solution + Bio‐Oss bone powder
Trial: 34217230
Drug: Tailored intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tailored intervention to reduce inappropriate psychotropic drug use
Trial: 34445969
Drug: Patient decision
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient decision aid (DA) on treatment of depression
Trial: 34445969
Drug: Matched treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched treatment preference
Trial: 34872085
Drug: Blood kidney
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood kidney injury molecule 1 (KIM-1)
Trial: 35983809
Drug: Tadalafil 5
RxNorm normalized name: tadalafil 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 5 mg every 3 days
Trial: 39665506
Drug: Methylphenidate (20
RxNorm normalized name: methylphenidate (20/80 release) 25 mg/24 hr oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (20 mg)
Trial: 34302350
Drug: Prenatal cholecalciferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenatal cholecalciferol (vitamin D-3) dose of 0, 4200, 16,800, or 28,000 IU/wk from 17 to 24 wk of gestation followed by placebo to 6 mo postpartum
Trial: 34302350
Drug: Various biological,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various biological, sociodemographic, and laboratory-related characteristics including feeding practices
Trial: 33648870
Drug: Renal-specific oral
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renal-specific oral nutritional supplement (RS-ONS) during hemodialysis sessions, given in two portions: 100 mL after 1 hour and 137 mL 45 minutes before the end of hemodialysis.
Trial: 33648870
Drug: Renal-specific oral
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renal-specific oral nutritional supplement (RS-ONS) at home.
Trial: 32960094
Drug: Ethanol 86%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol 86% v/v gel
Trial: 32960094
Drug: Ethanol 89.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol 89.5% v/v solution
Trial: 32960094
Drug: Ethanol 72.4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol 72.4% v/v solution
Trial: 32960094
Drug: Reference solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference solution (70% v/v ethanol)
Trial: 32428656
Drug: Herbal medicine
RxNorm normalized name: Herbal medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal medicine use
Trial: 32428656
Drug: Factors associated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Factors associated with herbal medicine use
Trial: 39621424
Drug: Sham therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham therapy
Trial: 35856224
Drug: Empagliflozin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin (10 mg, once a day, orally)
Trial: 33024552
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea (three cups/day after meals) + usual treatment (deferasirox iron chelator and on demand blood transfusion)
Trial: 33024552
Drug: Control (only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (only usual treatment)
Trial: 35201674
Drug: Erenumab 70
RxNorm normalized name: Erenumab 70 mg/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erenumab 70 mg (EM)
Trial: 35201674
Drug: Erenumab 70
RxNorm normalized name: Erenumab 70 mg/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erenumab 70 mg (overall population)
Trial: 35582897
Drug: Dextrose gel
RxNorm normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose gel followed by breastfeeding
Trial: 32321172
Drug: Heparin prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin prophylaxis